TY - JOUR
T1 - Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer
AU - Badrising, Sushil K.
AU - van der Noort, Vincent
AU - Hamberg, Paul
AU - Coenen, Jules L. L. M.
AU - Aarts, Maureen J.
AU - van Oort, Inge M.
AU - van den Eertwegh, Alfons J. M.
AU - Los, Maartje
AU - van den Berg, H. Pieter
AU - Gelderblom, Hans
AU - Vrijaldenhoven, Suzan
AU - Kerver, Emile D.
AU - van Voorthuizen, Theo
AU - de Jong, Igle J.
AU - Haanen, John B.
AU - Bergman, Andries M.
AU - Dutch Uro-Oncol Study Grp DUOS
PY - 2016
Y1 - 2016
N2 - Objective: To evaluate the efficacy of enzalutamide (Enz) as fourth- or fifth-line treatment in men with metastasized castration-resistant prostate cancer (mCRPC), by analyzing a retrospective cohort of heavily pretreated patients. Methods: We evaluated toxicity, overall survival (OS), progression-free survival (PFS) and time to prostate-specific antigen (PSA) progression data from 47 CRPC patients treated with fourth-or fifth-line Enz. Results: All patients were treated with docetaxel and abiraterone acetate and 42 patients (89%) with cabazitaxel. The median age of the patients was 69 years (IQR, 63-73.5), 79% had bone metastases, 55% had lymph node metastases, and 17% had visceral metastases. The median duration of Enz treatment was 12.0 weeks (IQR, 8.3-20.4), and 11 patients (23%) responded to Enz (maximum PSA decline >= 50%). In general, Enz was well tolerated, with the most frequently reported adverse events being fatigue and nausea. The median OS was 40.1 weeks (95% CI, 25.4-61.4), the median PFS was 12.1 weeks (95% CI, 9.9-14.0) and the median time to PSA progression was 15.7 weeks (95% CI, 14.0-28.7). Conclusions: Analysis of this retrospective cohort suggests that Enz is well tolerated and that there is a 23% response rate in heavily pretreated CRPC patients, which is comparable with third-line treatment outcomes. (C) 2016 S. Karger AG, Basel
AB - Objective: To evaluate the efficacy of enzalutamide (Enz) as fourth- or fifth-line treatment in men with metastasized castration-resistant prostate cancer (mCRPC), by analyzing a retrospective cohort of heavily pretreated patients. Methods: We evaluated toxicity, overall survival (OS), progression-free survival (PFS) and time to prostate-specific antigen (PSA) progression data from 47 CRPC patients treated with fourth-or fifth-line Enz. Results: All patients were treated with docetaxel and abiraterone acetate and 42 patients (89%) with cabazitaxel. The median age of the patients was 69 years (IQR, 63-73.5), 79% had bone metastases, 55% had lymph node metastases, and 17% had visceral metastases. The median duration of Enz treatment was 12.0 weeks (IQR, 8.3-20.4), and 11 patients (23%) responded to Enz (maximum PSA decline >= 50%). In general, Enz was well tolerated, with the most frequently reported adverse events being fatigue and nausea. The median OS was 40.1 weeks (95% CI, 25.4-61.4), the median PFS was 12.1 weeks (95% CI, 9.9-14.0) and the median time to PSA progression was 15.7 weeks (95% CI, 14.0-28.7). Conclusions: Analysis of this retrospective cohort suggests that Enz is well tolerated and that there is a 23% response rate in heavily pretreated CRPC patients, which is comparable with third-line treatment outcomes. (C) 2016 S. Karger AG, Basel
KW - Cross-resistance
KW - Treatment sequence
KW - Heavily pretreated patients
KW - Time interval
KW - Docetaxel
KW - Abiraterone
KW - Cabazitaxel
KW - Radium-223
KW - HEAVILY PRETREATED PATIENTS
KW - ABIRATERONE TREATMENT
KW - ANTITUMOR-ACTIVITY
KW - INCREASED SURVIVAL
KW - DOCETAXEL
KW - CABAZITAXEL
KW - CHEMOTHERAPY
KW - MITOXANTRONE
KW - PREDNISONE
KW - MDV3100
U2 - 10.1159/000448219
DO - 10.1159/000448219
M3 - Article
SN - 0030-2414
VL - 91
SP - 267
EP - 273
JO - Oncology : journal of clinical and experimental cancer research
JF - Oncology : journal of clinical and experimental cancer research
IS - 5
ER -